You wouldn’t brake your car while stepping on the gas — or wash down a sleeping pill with espresso. Yet many people taking common Alzheimer’s disease medications—cholinesterase inhibitors—are given medications with anticholinergic properties, which oppose their effects. Group Health Research Institute scientists investigated how often that happens and reported on the consequences in an “Early View” study e-published in the Journal of the American Geriatrics Society.
“Cholinesterase inhibitors are today’s primary therapy for slowing Alzheimer's disease,” said study leader Denise Boudreau, PhD, RPh, an associate scientific investigator at Group Health Research Institute. “Anticholinergic properties are often found in drugs commonly used to treat gastrointestinal disorders, allergies, urinary incontinence, depression, and Parkinson’s disease, and they can have negative effects on cognition and function in the elderly. There’s concern that if someone is taking both types of drugs—cholinesterase inhibitors and anticholinergic medications—they will antagonize each other, and neither will work.”
In clinical trials, cholinesterase inhibitors show modest effects against the functional and cognitive decline of people with Alzheimer’s disease. These medications, such as donepezil (Aricept) work by inhibiting the breakdown of acetylcholine, which sends signals in the nervous system. By contrast, anticholinergics—such as diphenhydramine (Benadryl) and oxybutynin (Ditopan)—block the action of acetylcholine. Since the two types of drugs have opposite effects, it makes sense not to give both kinds of drugs to an individual person. But until Dr. Boudreau’s study, few researchers had explored how often patients are prescribed both types of medications and which harms this might cause.
Dr. Boudreau and colleagues conducted a retrospective cohort study of 5,625 people aged 50 or older who received a new prescription for cholinesterase inhibitors between 2000 and 2007. The researchers used electronic pharmacy records of Group Health Cooperative and Kaiser Permanente Colorado, nonprofit health care systems that together provide care to more than a million people. The research team found patients who also had a prescription for anticholinergics from the year before their cholinesterase prescription until the analysis ended on December 31, 2008, or the patient left the health care system or died. The study was the first to use state death records and insurance claims for nursing home care to look for effects of taking both drug types.
The researchers found:
Of the cholinesterase inhibitor users, 37 percent were also taking at least one anticholinergic drug, and more than 11 percent took two or more. This was similar to other studies of Medicare beneficiaries.For those using both medication types, dual use generally lasted three to four months, but 25 percent used both classes of drugs for more than a year.
Anticholinergics were already being used in 23 percent of people receiving a new cholinesterase inhibitor prescription, and 77 percent continued, even after starting the cholinesterase inhibitor.
Subjects using both medication types were not more likely to enter a nursing home or to die than those taking only cholinesterase inhibitors.
“It’s reassuring that we did not observe an association between simultaneous use of the two types of drugs and increased risk of death or nursing home placement,” said Dr. Boudreau. “But concomitant use of these drugs is, at the very least, not optimal clinical practice.” Preventing concurrent use of opposing drugs could also be a chance to reduce waste in health care spending, since a month of donepezil treatment costs approximately $180.
One reason that health care providers might prescribe conflicting medications is that dementia patients often have multiple medical conditions. Also, anticholinergics are often given to counteract the side effects of cholinesterase inhibitors, which are one of the few available treatments for people with Alzheimer’s. Dr. Boudreau hopes the study raises awareness about the potential inappropriateness of prescribing both types of drugs—and stimulate discussions about the best way to make therapeutic decisions for people with Alzheimer’s.
“Providers, families, and patients should carefully consider the extent to which demonstrated benefits or harms in an individual patient justify long-term use of these drugs,” said Dr. Boudreau. “A good first step is to have clearly agreed-upon goals for therapy and a plan to monitor for effects and side effects.” Now Group Health Research Institute scientists have started to work with Group Health Cooperative on steps like these to improve the quality of care.
A contract with the National Heart, Lung, and Blood Institute supported this research.
Dr. Boudreau’s co-authors are Senior Biostatistician Onchee Yu, MS, Group Health Vice President for Research and Executive Director Eric B. Larson, MD, MPH, and Jeanene Johnson, MPH, of Group Health Research Institute, in Seattle; Shelly L. Gray, PharmD, MS, of the University of Washington; and Marsha A. Raebel, PharmD, of the Kaiser Permanente Colorado Institute for Health Research and the University of Colorado at Denver. Drs. Boudreau and Larson are also affiliated with the University of Washington.The Journal of the American Geriatrics Society
Rebecca Hughes | EurekAlert!
When wheels and heads are spinning - DFG research project on motion sickness in automated driving
22.05.2019 | Technische Universität Berlin
A new approach to targeting cancer cells
20.05.2019 | University of California - Riverside
Physicists at the University of Basel are able to show for the first time how a single electron looks in an artificial atom. A newly developed method enables them to show the probability of an electron being present in a space. This allows improved control of electron spins, which could serve as the smallest information unit in a future quantum computer. The experiments were published in Physical Review Letters and the related theory in Physical Review B.
The spin of an electron is a promising candidate for use as the smallest information unit (qubit) of a quantum computer. Controlling and switching this spin or...
Engineers at the University of Tokyo continually pioneer new ways to improve battery technology. Professor Atsuo Yamada and his team recently developed a...
With a quantum coprocessor in the cloud, physicists from Innsbruck, Austria, open the door to the simulation of previously unsolvable problems in chemistry, materials research or high-energy physics. The research groups led by Rainer Blatt and Peter Zoller report in the journal Nature how they simulated particle physics phenomena on 20 quantum bits and how the quantum simulator self-verified the result for the first time.
Many scientists are currently working on investigating how quantum advantage can be exploited on hardware already available today. Three years ago, physicists...
'Quantum technologies' utilise the unique phenomena of quantum superposition and entanglement to encode and process information, with potentially profound benefits to a wide range of information technologies from communications to sensing and computing.
However a major challenge in developing these technologies is that the quantum phenomena are very fragile, and only a handful of physical systems have been...
Working group led by physicist Professor Ulrich Nowak at the University of Konstanz, in collaboration with a team of physicists from Johannes Gutenberg University Mainz, demonstrates how skyrmions can be used for the computer concepts of the future
When it comes to performing a calculation destined to arrive at an exact result, humans are hopelessly inferior to the computer. In other areas, humans are...
29.04.2019 | Event News
17.04.2019 | Event News
15.04.2019 | Event News
23.05.2019 | Materials Sciences
23.05.2019 | Materials Sciences
23.05.2019 | Physics and Astronomy